stars 1 stars 2 stars 3

Boryung advances health through two pillars. In pharmaceuticals, the company leads chronic disease care with the Kanarb family—its proprietary original drug—and is positioned as a global specialist in cytotoxic anti-cancer drugs. These products are produced at the EU-GMP-certified Yesan Smart Factory, which also provides world-class CDMO services and ensures the stable global supply of essential treatments. In space-based healthcare, Boryung pioneers research infrastructure and opportunities to support human survival in extreme environments. By actively collaborating with global partners to secure independent research space, the company expands opportunities for R&D and extends its mission to address health challenges both on Earth and beyond.

Boryung Questions

The Boryung annual revenue was $640.4 million in 2026.

Sue Kim is the CEO of Boryung.

61 people are employed at Boryung.

Top Boryung Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users